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Pathogenic mutations in the Leu-
cine-rich repeat kinase 2 (LRRK2)
increase its activity leading to
increased phosphorylation of Rab
proteins. Here we introduce a
sensitive and accurate assay to
measure increased phospho Rab
levels using synthetic stable iso-
tope-labeled analogues for both
phosphorylated and non-phos-
phorylated tryptic peptides sur-
rounding Rab10-Thr73. Com-
pared to healthy controls, carriers
of mutated LRRK2 had 1.9-fold
and those with VPS35 mutation
3.7-fold increased pRab10 levels
in their neutrophils. Our generic
MS-based assay helps to stratify
PD patient and determine LRRK2
inhibitor efficiency in clinical trials.
Graphical Abstract
Highlights
 MS-based clinical assay that accurately determines phospho Rab10 occupancy.
 Stable isotope labeled phosphopeptide injected as a standard with endogenous tryptic phospho
Rab peptide for accurate ratio determination.
 Determination of pRab levels in neutrophils of Parkinson disease patients.
 Relevance of pRab levels as marker of PD.
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Accurate MS-based Rab10 Phosphorylation
Stoichiometry Determination as Readout for
LRRK2 Activity in Parkinson’s Disease
ÖzgeKarayel1 , Francesca Tonelli2 , Sebastian VirreiraWinter1 , Phillip E. Geyer1 ,
Ying Fan2, Esther M. Sammler2,3, Dario R. Alessi2, Martin Steger1,*, andMatthias Mann1,*
Pathogenic mutations in the Leucine-rich repeat kinase 2
(LRRK2) are the predominant genetic cause of Parkinson’s
disease (PD). They increase its activity, resulting in aug-
mented Rab10-Thr73 phosphorylation and conversely,
LRRK2 inhibition decreases pRab10 levels. Currently, there
is no assay to quantify pRab10 levels for drug target
engagement or patient stratification. To meet this chal-
lenge, we developed an high accuracy and sensitivity
targeted mass spectrometry (MS)-based assay for deter-
mining Rab10-Thr73 phosphorylation stoichiometry in
human samples. It uses synthetic stable isotope-labeled
(SIL) analogues for both phosphorylated and nonphos-
phorylated tryptic peptides surrounding Rab10-Thr73 to
directly derive the percentage of Rab10 phosphorylation
from attomole amounts of the endogenous phosphopep-
tide. The SIL and the endogenous phosphopeptides are
separately admitted into an Orbitrap analyzer with the
appropriate injection times. We test the reproducibility of
our assay by determining Rab10-Thr73 phosphorylation
stoichiometry in neutrophils of LRRK2 mutation carriers
before and after LRRK2 inhibition. Compared with healthy
controls, the PD predisposing mutation carriers LRRK2
G2019S and VPS35 D620N display 1.9-fold and 3.7-fold
increased pRab10 levels, respectively. Our generic MS-
based assay further establishes the relevance of pRab10 as
a prognostic PDmarker and is a powerful tool for determin-
ing LRRK2 inhibitor efficacy and for stratifying PD patients
for LRRK2 inhibitor treatment.
Parkinson's disease (PD) is the second most common neu-
rodegenerative condition, and no disease-modifying thera-
pies exist to date (1, 2). Although most PD cases are idio-
pathic, mutations in several genes have been linked to
familial forms of the disease (3). Among those, mutations in
the Leucine-rich repeat kinase 2 (LRRK2) comprise the pre-
dominant genetic cause of PD and account for 1% of spo-
radic and 4% of familial cases worldwide, and much higher
in some populations (4). At least six pathogenic missense
mutations in LRRK2, including the most frequent G2019S
substitution, have been identified (5) and several studies con-
firmed that these mutations increase its kinase activity (5–8).
LRRK2-associated PD is clinically largely indistinguishable
from idiopathic PD, suggesting that LRRK2 inhibition may be
a useful a therapy for a larger group of patients (4). Clinical
trials with selective LRRK2 kinase inhibitors are ongoing and
have already passed phase 1.
Downstream targets of the LRRK2 kinase have long been
enigmatic and controversial, but using genetic mouse mod-
els, specific inhibitors and a novel phosphoproteomics work-
flow, we have recently identified and verified a subset of
Rab GTPases (Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10,
Rab12, Rab29, Rab35, and Rab43) as bona fide substrates
(8, 9). Among these, Rab10 appears to be a key physiological
kinase substrate (8–14). We found that LRRK2 directly phos-
phorylates Rab10 at Thr73 and all known pathogenic forms
of LRRK2 enhance this phosphorylation (8, 9). Intriguingly,
the PD-associated D620N mutation of the retromer complex
protein VPS35 also activates LRRK2 kinase activity, which in
turn results in augmented Rab10 phosphorylation (15). Thus,
multiple PD-associated factors are interconnected and dysre-
gulation of a common LRRK2-Rab signaling pathway appears
to be an underlying cause of PD.
The LRRK2 autophosphorylation site Ser1292 has been
widely used for assessing LRRK2 kinase activity (16–19).
However, its stoichiometry (percentage of molecules phos-
phorylated) appears to be extremely low and there is no sen-
sitive phospho-specific antibody available to reliably detect
and quantify phosphorylation at this site (6, 20, 21). We
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recently developed several high-affinity antibodies for detecting
pRab proteins in cells and in tissues (14). Among those,
a highly specific clone detects pThr73 levels in human periph-
eral blood cells of (mutant) LRRK2 G2019S and VPS35-D620N
carriers with Parkinson's disease (11, 15). Although pRab10
levels were markedly increased in VPS35 D620N carriers,
no statistically significant differences in pRab10 levels were
detected by immunoblotting analysis when comparing con-
trols to LRRK2-G2019S carriers in peripheral blood mononu-
clear cells (PBMCs) and neutrophils (11, 15). The reproduci-
ble quantification of immunoblots, particularly the detection
of small (,2-fold) changes is challenging. In contrast, MS-
based quantification has become a gold standard and has
several advantages over traditional biochemical methods, as
it is more specific and potentially more accurate. Importantly,
MS allows simultaneous detection of both the phosphory-
lated peptide and the total protein pool and hence enables
the direct calculation of the absolute fraction of the phospho-
rylated protein, also known as phosphorylation stoichiometry
or occupancy (22).
There are several strategies differing in their accuracy,
throughput, and applicability for measuring phosphorylation
stoichiometry by MS (22–27). One way is to compare the
intensities of modified and unmodified peptides by label-free
proteomics (27). However, because of potential differences in
ionization efficiencies, the MS signals of individual peptides
cannot be directly compared with each other. Stoichiometry
determination based on heavy-to-light ratios of stable iso-
tope-labeled (SIL) analogs of phosphorylated and nonphos-
phorylated proteolytic peptides and their endogenous coun-
terparts can overcome this problem and allow a much more
sensitive and precise readout for monitoring kinase activity
(22, 23). Alternatively, a SIL recombinant protein that is
chemically or enzymatically phosphorylated can also be used
as the spike-in standard (28, 29). MS strategies determining
stoichiometry that are combined with tailored targeted meth-
ods are especially suited for accurate quantification of low
levels of a given phosphorylated analyte (30). Instruments
with an Orbitrap mass analyzer can be operated in targeted
scan modes such as high-resolution selected ion monitoring
(SIM) or parallel reaction monitoring (PRM). In both methods,
precursor ions are isolated with a narrow m/z range by a
quadrupole mass filter before introduction into the Orbitrap
analyzer, thereby providing increased signal to noise ratio for
the ion of interest and allowing attomole-level limits of detec-
tion (31, 32). As no fragmentation is involved in SIM, quantifi-
cation of selected ions relies on the high resolution in the
Orbitrap mass analyzer alone. In contrast, in PRM, fragment
ions are used for quantification of the peptide. Although that
approach is more specific, the overall sensitivity of PRM can
be lower, as the signal of a given precursor ion is distributed
across multiple fragments (32).
Here we describe an accurate and highly-sensitive MS-
assay for determining the Rab10-Thr73 phosphorylation
stoichiometry and how it changes in Parkinson’s disease.
We evaluate it by comparing Rab10-Thr73 phosphorylation lev-
els in healthy controls, idiopathic PD patients, and PD patients
with defined genetic cause. Our assay enables the detection of
subtle changes in Rab10 phosphorylation, which are beyond
what is detectable by typical immunoassays. We show that
pRab10 stoichiometry when measured precisely using our
assay can serve as a robust target engagement and patient
stratification marker in clinical studies.
EXPERIMENTAL PROCEDURE
Experimental Design and Statistical Rationale—The experi-
mental design and statistical rationale for each of the
experiments conducted in this study are described in
detail in each subsection and figure legend. Briefly, all
neutrophil samples isolated from individuals were meas-
ured with technical replicates (n = 3). The LOQ experiment
and IP experiments were also measured in technical repli-
cates (n = 3). For CV experiments, we repeated MS meas-
urements (analytical), and the workflow in the same gel
(intra-assay) or in different gels (inter-assay) using the
same phosphoprotein standard (n = 6).
Study Participants and Blood Sample Collection—Our assay
was applied in the neutrophils collected from 14 healthy con-
trols, three idiopathic PD patients, four LRRK2 G2019S and
three VPS35 D620N mutation carriers with PD.
For setting up and validating our assay, we recruited seven
volunteers from the Department of Proteomics and Signal
Transduction at the Max Planck Institute of Biochemistry
who kindly donated blood for our study. The data shown in
Figs. 1 and 3 and supplemental Figs. S1–S3 are derived
blood samples from healthy donors, which provided a written
informed consent, with prior approval of the ethics committee
of the Max Planck Society.
For the experiments shown in Fig. 4, neutrophil lysates
derived from either idiopathic PD patients, PD patients carrying
a heterozygous LRRK2 G2019S or VPS35 D620N mutation or
nonPD controls were used that had been previously used for
publication ((11) and (15), respectively, supplemental Table S4).
All procedures were performed in compliance with the local
ethics review boards and all participants provided informed
consent. These lysates were subjected to MS analysis in a
blinded experimental set-up, with the identity of the lysates
only being revealed after completion of the MS analysis.
Reagents—MLi-2 was purchased from Tocris Bioscience
(cat# 5756). DIFP, HA-agarose and trypsin were from Sigma
and LysC was from Wako. Microcystin-LR was from Enzo
Life Sciences. Complete protease and phosphatase inhibitor
tablets were from Roche. SIL peptides in absolute quantities
(AQUA) were purchased from Sigma-Aldrich.
Antibodies—Anti-GAPDH (#5174), anti-HA (#3724), and
anti-Rab10 (#8127) were from Cell Signaling Technologies.
Rabbit mAb for total LRRK2 (UDD3, ab133518), Rab10 (T73)
antibody [MJF-R21] and polyclonal phospho-Rab (initially
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raised against Rab8) antibody [MJF-R20] that efficiently im-
munoprecipitated multiple LRRK2 phosphorylated Rab proteins
were purchased from Abcam (Burlingame, California). They
were custom-made by Abcam in collaboration with the Michael
J. Fox Foundation (Burlingame, California) (14, 33).
Plasmids—HA-Rab10 (DU44250) and Flag-LRRK2-Y1699C
(DU13165). Full datasheets and reagents are available on
https://mrcppureagents.dundee.ac.uk/.
Stable Isotope Labeling and Purification of the Rab10 Protein
Standard—Buffer A: 50mM HEPES pH 8.0, 500mM LiCl, 1mM
MgCl2, 100 mM GDP, 1mM TCEP and Elution buffer: Buffer
A1 500mM imidazole.
To obtain unlabeled Rab10 standard, human His-tagged
Rab10 (residues 1-175) construct from Rai et al. (34) was
expressed in E. coli BL21 (DE3) harboring the GroEL/S plas-
mid and protein expression was induced with isopropyl b-D-
1-thiogalactopyranoside overnight. Cells were lysed by soni-
cation in a buffer containing 50mM HEPES pH 8.0, 500mM
LiCl, 1mM MgCl2, 100 mM GDP, 1mM TCEP (Buffer A) supple-
mented with several protease inhibitors including 30 mM
FIG. 1.Rab10-pThr73 as a readout for LRRK2 activity in human peripheral blood neutrophils. A, Workflow for global proteome analy-
sis of human peripheral blood neutrophils. B, Proteins ranked according to their abundances across the global neutrophil proteome. Quar-
tiles are indicated with dashed lines. LRRK2 phosphorylated Rab proteins and other PD-associated proteins are highlighted in red and
blue, respectively. C, Western blot analysis of neutrophils (2/1 200 nM MLi-2, 30min) using anti-MJFF-pRAB10 (pThr73), Rab10 total and
GAPDH antibodies. D, Heat map of z-scored phosphopeptide intensities of LRRK2-phosphorylated Rab proteins from pRab immunopreci-
pitation of neutrophil lysates (2/1 200 nMMLi-2, 30min, 3 technical replicates, n = 2). Missing values are in grey. E, Targeted MS-quantified
Rab10-pThr73 and Rab43-pThr82 peptide intensities in immunoprecipitations of individual Rab10 and Rab43 proteins from neutrophils
(2/1 200 nM MLi-2, 30min). P-values were assessed using unpaired Student’s t test analysis. F, Limit of detection (LOD) of SIL Rab10-
pThr73 tryptic peptide (FHpTITTSYYR) with various acquisition methods; full MS, SIM, mxSIM and PRM. Linear ranges of the dilution
curves were assessed with singlets analyses of the SIL Rab10-pThr73 phosphopeptide (10 amol to 50 fmol, spiked-in a digest of HeLa). G,
Limit of quantification (LOQ) for the Rab10-pThr73 tryptic peptide measured in mxSIM mode. 25 fmol of light phosphopeptide was mixed
with variable amounts of its SIL counterpart (10 amol to 50 fmol) and spiked into a background of HeLa digest (3 technical replicates). Me-
dian ratios extracted from Skyline were plotted against the expected ratios.
MS-based Clinical Assay for PTMOccupancy Calculation
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Antipain and 50 mM Chymostain. Proteins were purified by
Ni-NTA affinity chromatography. Briefly, bound proteins
eluted with an imidazole gradient (25mM-500mM) and imid-
azole was removed by washing with 500 mM ATP containing
Buffer A. Further purification was done by ion-exchange
chromatography (Q-Sepharose) followed by size exclusion
chromatography using a Superdex 200 column. Peak frac-
tions containing recombinant protein were pooled. Identity
and purity of the standard protein were assessed by Maldi-
TOF MS and SDS-PAGE. To obtain labeled Rab10 standard,
we used an auxotrophic expression strain for arginine and ly-
sine (29, 35). Cultures were grown in PA5052 minimal autoin-
duction media containing heavy Arg10 and Lys8 and cells
were harvested for purification of SIL Rab10 protein standard
as described earlier.
In Vitro LRRK2 Kinase Assays—Recombinant LRRK2 G2019S
(Invitrogen, PV4881) and Rab proteins were incubated at 30°
C for 30min in kinase assay buffer (100mM Tris–HCl, pH 7.5,
50mM MgCl2, 5mM EGTA, 1mM GDP, 10mM DTT, 25mM
b-glycerol phosphate, 5mM Sodium orthovanadate, and
50 mM ATP). The reaction was terminated by addition of
HG-10-102-0.
Cell Culture and Transfection—HEK293 and MEFs (WT and
LRRK2-R1441G) cells were cultured in Dulbecco’s modified
Eagle's medium (Glutamax, Invitrogen) supplemented with
10% fetal calf serum, 100 U/ml penicillin and 100mg/ml
streptomycin. Transient transfections were performed 48 h
before cell lysis using polyethylenimine PEI (Polysciences).
Transfected cells were subjected to DMSO or MLi-2 (dis-
solved in DMSO) treatments at concentrations and periods of
time as indicated in each figure legend. All cells were tested
for mycoplasma contamination and overexpressing lines
were verified by western blot analysis.
Neutrophil Isolation, Characterization, Treatments and Lysis—
The procedure for neutrophil collection was done as de-
scribed in detail in our video article (36). Pipetting of human
blood were undertaken in a biological safety cabinet. Briefly,
10ml of blood was collected into a blood collection tube and
mixed gently by inverting tubes. Next, it was transferred into
a 50ml conical tube and mixed gently with 100ml of EDTA
Stock Solution (100mM EDTA in PBS (PBS)). Neutrophils
were isolated by immune-magnetic negative isolation using
the MACSxpress® Neutrophil Isolation Kit (Miltenyi Biotec,
Cat# 130-104-434). For 8ml of blood, one vial of ‘Isolation
Cocktail’ (magnetic beads) from the neutrophil isolation kit,
delivered as a lyophilized pellet, was reconstituted by adding
0.25ml of Buffer A and 0.25ml of Buffer B in that order. The
mixture was mixed by gently pipetting and added to 8ml of
whole blood in 15ml falcon tube. The blood sample contain-
ing the mixture was gently mixed by inversion and incubated
at room temperature for 5min. The falcon tube was next
placed into the magnetic field of the MACSxpress Separator
(# 130-098-308) for 15min. The magnetically labeled cells
(non-neutrophils) adhere to the wall of the tube whereas the
aggregated erythrocytes sediment to the bottom. The super-
natant (; 7ml) containing the enriched neutrophils was care-
fully pipetted into a new 15ml falcon tube, avoiding touching
the magnetic beads attached to the sides of the falcon
tube as well as the red blood cells at the bottom of the
tube. The supernatant containing the isolated neutrophils
was centrifuged at 300 3 g for 10min at room temperature
(acceleration and deceleration is both 5 using a Beckman
Coulter Allegra X-15R Centrifuge). To ensure the removal
of erythrocytes, the pelleted neutrophil cells were resus-
pended in 10ml of 1 3 Red Blood Cell Lysis Solution
(# 130-094-183), incubated for 10min at room temperature
and centrifuged at 300 3 g for 10min at room temperature.
To assess the purity and recovery of the enriched neutro-
phils an aliquot was taken at this stage and we later fluo-
rescently stained cells with CD14-PerCP, CD15-PE, CD16-
APC, and CD193-FITC and analyzed by flow cytometry.
Cell debris, dead cells were excluded from the analysis
based on scatter signals and DAPI. Finally, the cell pellet
was resuspended with 10ml room temperature RPMI 1640
media by gentle pipetting. At this stage, purified cells were
subjected to MLi-2 (dissolved in DMSO) treatment at con-
centrations and periods of time as indicated in each figure
legend. An equivalent volume of DMSO was added to neg-
ative control samples. Following treatment, cells were pel-
leted through centrifugation at 500 g for 5min. Cells were
then resuspended in 5ml of ice-cold PBS and centrifuged
again at 500 g for 5min. The supernatant was carefully
removed by pipetting. Cells were lysed in 300ml of ice-cold
Nonidet P-40 buffer (50mM Tris–HCl, pH 7.5, 1% (v/v) Tri-
ton X-100, 1mM EGTA, 1mM sodium orthovanadate, 50mM
NaF, 0.1% (v/v) 2-mercaptoethanol, 10mM 2-glycerophos-
phate, 5mM sodium pyrophosphate, 0.1mg/ml microcystin-
LR, 270mM sucrose, 0.5mM DIFP (Sigma, Cat# D0879)
supplemented with protease and phosphatase inhibitors
(Roche)). Lysate was clarified by centrifugation at 16,000 rpm
for 15min at 4 °C after a liquid nitrogen freeze-thaw cycle.
Protein concentration was measured using Bradford assay
(Thermo Scientific), snap-frozen and stored at 280 °C. The
whole procedure from the collection of blood to the freezing
of neutrophil lysates was up to 4 h.
Immunoblot Analysis—Cell lysates were mixed with 4 3
SDS–PAGE loading buffer [250mM Tris–HCl, pH 6.8, 8%
(w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) Bromphenol Blue
and 4% (v/v) 2-mercaptoethanol] to final total protein con-
centration of 1mg/ml and heated at 85 °C for 10min. Samples
were loaded onto NuPAGE Bis-Tris 4–12% gel (Invitrogen)
and electrophoresed at 180 V for 1 h with MOPS SDS run-
ning buffer followed by transfer onto the nitrocellulose mem-
brane (GE Healthcare, Amersham Pharmacia Biotech Protran
Supported 0.45 mM NC) at 100 V for 90min on ice in the
transfer buffer (48mM Tris–HCl and 39mM glycine). Mem-
brane was then cropped into pieces: from top of the mem-
brane to 75 kDa to incubate with rabbit anti-LRRK2 UDD3
MS-based Clinical Assay for PTMOccupancy Calculation
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antibody, from 75 to 30kDa to incubate with rabbit anti-
GAPDH antibody and from 30kDa to the bottom of the mem-
brane to incubate with rabbit monoclonal antibodies for anti-
Rab10-pThr73 or anti-Rab10. Antibodies diluted in 5% (w/v)
BSA in TBS-T to a final concentration of 1mg/ml. All blots
were incubated in primary antibody overnight at 4 °C. Before
secondary antibody incubation, membranes were washed
three times with TBS-T (20mM Tris/HCl, pH 7.5, 150mM NaCl
and 0.2% (v/v) Tween 20) for 10min each. Membranes were
incubated with secondary antibody multiplexed with goat
anti-rabbit diluted in 5% (w/v) nonfat dry milk (NFDM) in
TBS-T (1:5000 dilution) for 1 h at room temperature. They
were next washed with TBS-T three times for 10min. Protein
bands were detected using an ECL solution (Amersham
Pharmacia Biotech ECL Western Blotting Detection Reagents
(GE Healthcare)) and the ImageQuant LAS 4000 imaging sys-
tem. For the immunoblots shown in Fig. 4A and 4F, the
membranes were developed using the LI-COR Odyssey CLx
Western Blot imaging system.
Cells Lysis and Pull-Downs—Cells were lysed in either Noni-
det P-40 buffer (50mM Tris-HCl, pH 7.5, 120mM NaCl, 1mM
EDTA, 6mM EGTA, 20mM NaF, 15mM sodium pyrophosphate
and 1% Nonidet P-40 supplemented with protease and
phosphatase inhibitors (Roche)) or Triton X-100 buffer (50mM
Tris–HCl, pH 7.5, 1% (v/v) Triton X-100, 1mM EGTA, 1mM so-
dium orthovanadate, 50mM NaF, 0.1% (v/v) 2-mercaptoetha-
nol, 10mM 2-glycerophosphate, 5mM sodium pyrophosphate,
0.1mg/ml microcystin-LR, 270mM sucrose, 0.5mM DIFP
(Sigma, Cat# D0879) supplemented with protease and phos-
phatase inhibitors (Roche)). Lysates were clarified by centrifu-
gation at 16,000 rpm for 15min at 4 °C after a liquid nitrogen
freeze-thaw cycle. Protein concentrations were measured
using Bradford assay (Thermo Scientific), snap-frozen and
stored at 280 °C. For HA pulldowns, lysates were incubated
with HA-agarose resin for 2 h (25ml resin per 100 mg of
lysates). For immunoprecipitation using total Rab10 or phos-
pho-Rab, lysates were incubated with antibodies in manufac-
turer’s recommend dilutions or concentrations overnight at
4 °C and subsequently incubated with 25ml of Protein-A/G-
agarose beads for 2 h at 4 °C. To remove unspecific binders,
beads were washed twice with matching lysis buffer and
twice with 50mM Tris-HCl (pH 7.5). SIL phosphorylated
Rab10 protein was mixed with the beads at this step if used
as standrad. Washes were followed by on-bead digestion
overnight at 37 °C with trypsin (;500ng/pulldown in urea
buffer [2M urea dissolved in 50mM ammonium bicarbonate]
or SDC buffer [1% (w/v) SDC in 100mM Tris-HCL pH 8.5]).
The resulting peptides were processed as described in ‘LC–
MS/MS sample preparation’.
In-Gel Digestion Protocol—Cell lysates were mixed with
4 3SDS/PAGE sample buffer (250mM Tris/HCl, pH 6.8, 8%
(w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) Bromphenol Blue
and 4% (v/v) 2-mercaptoethanol) and heated at 85 °C for
5min. SIL Rab10 phosphoprotein was mixed with samples at
this step if used as standard. 20-30mg sample (5mg per MS
analysis) was loaded onto NuPAGE Bis-Tris 4-12% gel (Invi-
trogen) and electrophoresed at 180 V. After SDS-PAGE, gel
was washed once with deionized water and stained with
0.1% Coomassie Blue R250 in 10% acetic acid, 40% metha-
nol and 60% deionized water for 20min and subsequently
destained by soaking for at least 2 h in 10% acetic acid,
40% methanol, and 60% deionized water with at least two
changes of the solvent (until the background is nearly clear).
Gel band corresponding to 20-30kDa is excised and
chopped into smaller pieces (; 1 3 1mm) and placed in
clean 1.5ml tubes. Gel pieces are washed two or three times
with 50% 50mM ABC/50% EtOH for 20min at RT and then
completely dehydrated by incubating for 10min in absolute
EtOH. Samples were dried in a speed-vac for 10min (45 °C)
until the gel pieces were bouncing in the tube. Gel pieces
were rehydrated in 300ml of 1% (w/v) SDC buffer (10mM
TCEP, 40mM CAA, trypsin in 100mM Tris-HCL pH 8.5) per
sample and placed at 37 °C overnight. The next day, 300ml
of isopropanol buffer (1% TFA in isopropanol) was added
and shaken for 10min and spin down. The liquid was trans-
ferred into a fresh tube. Further 200ml of isopropanol buffer
was added to the gel pieces and shaken vigorously for
20min at RT. It was combined with that from the previous
step. Samples were directly loaded onto SDB-RPS stage
tips and processed as described in ‘LC–MS/MS sample
preparation’.
Human Neutrophil Proteome Digestion, in-StageTip Purification
and Fractionation—The neutrophil cell pellet was prepared
with the iST Kit for proteomic sample preparation (P.O.
00001, PreOmics GmbH). In brief, this involved denaturation,
alkylation, digestion and peptide purification. Reduction of di-
sulfide bridges, cysteine alkylation and protein denaturation
was performed at 95 °C for 10min. After a 5min cooling step
at room temperature, trypsin and LysC were added to the
mixture at a ratio of 1:100 mg of enzyme to micrograms of
protein. Digestion was performed at 37 °C for 1 h. 20mg of
peptides was loaded on two 14-gauge SDB-RPS StageTip
plugs. Samples were directly loaded onto SDB-RPS Stage-
Tips processed as described in ‘LC–MS/MS sample prepara-
tion’. Clean peptides were separated using the high-pH
reversed-phase ‘Spider fractionator’ into 24 fractions as
described previously to generate deep proteomes (37).
LC–MS/MS Sample Preparation—StageTips (38) were pre-
pared by inserting two 16-gauge layers of a SDB-RPS matrix
(Empore) into a 200ml pipette tip using an in-house prepared
syringe device as described previously (39). The StageTips
were centrifuged using an in-house 3D-printed StageTip cen-
trifugal device at 1500 g. The acidified peptides (1% TFA v/v)
were loaded onto the StageTips that were later washed with
1% TFA in isopropanol and subsequently 2% ACN/0.2%
TFA. Elution was performed using 60ml of 50% ACN/1.25%
NH4OH or 80% ACN/1.25% NH4OH. Eluates were collected
in PCR tubes and dried using a SpeedVac centrifuge
MS-based Clinical Assay for PTMOccupancy Calculation
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(Eppendorf, Concentrator plus) at 60 °C. Peptides were
resuspended in buffer A* (2% ACN/0.1% TFA) and briefly
sonicated (Branson Ultrasonics) before LC–MS-MS analysis.
To calculate absolute Rab10-pThr73 occupancy, we spiked
SIL phosphorylated and nonphosphorylated counterpart pep-
tides into samples at this step. Light contamination in heavy
standards was not detected up to 100 fmol of spike-in
amount (the highest amount tested). Given that the detection
limits of these peptides with our mxSIM assay were below 50
amol, light contamination is determined to be ,0.05%.
LC–MS/MS Measurements—Peptides were loaded on a 20
or 50cm reversed phase column (75 mM inner diameter,
packed in house with ReproSil-Pur C18-AQ 1.9 mM resin
(Dr. Maisch GmbH)). Column temperature was maintained at
60 °C using a homemade column oven. An EASY-nLC 1200
system (Thermo Fisher Scientific) was directly coupled online
with the mass spectrometer (Q Exactive HF-X, Thermo Fisher
Scientific) via a nano-electrospray source, and peptides were
separated with a binary buffer system of buffer A (0.1% for-
mic acid (FA)) and buffer B (80% acetonitrile plus 0.1% FA),
at a flow rate of 300 nl/min. Peptides were eluted with a
45min gradient of 5–60% buffer B (0.1% (v/v) FA, 80% (v/v)
ACN). After each gradient, the column was washed with 95%
buffer B for 5min.
The mass spectrometer was programed to acquire in tar-
geted scan mode in which every full scan with resolution
60,000 at 200 m/z (3 3 106 ions accumulated with a maxi-
mum injection time of 20ms) was followed by two multi-
plexed selected ion monitoring (mxSIM) scans employing
multiplexing degree of two to record both light (endogenous)
and heavy counterpart simultaneously for either phosphory-
lated or nonphosphorylated Rab10-pT73 tryptic peptides.
Each SIM scan covered a range of m/z 150–2000 with resolu-
tion 120,000 (105 ions accumulated with a maximum injection
time of 230ms for both light and heavy counterparts, 1.4 m/z
isolation window and 0.4 m/z isolation offset). m/z values of
doubly-charged Rab10-pT73 tryptic (FHpTITTSYYR) light and
heavy peptides (arginine labeled (13C, 15N)) were defined as
follows: 684.8028 and 689.8070 whereas doubly-charged
Rab10 nonphosphorylated tryptic (FHTITTSYYR) light and
heavy peptides (arginine labeled (13C, 15N)) were targeted at
m/z of 644.8197 and 649.8238.
For the LOD experiment (Fig. 1), the mass spectrometer
was programed to acquire in either full scan mode alone or
SIM or PRM combined with a full scan. Full scan acquisition
was performed with a resolution of 120,000 at 200 m/z (3 3
106 ions accumulated with a maximum injection time of
230ms) to cover the scan range of 350–1650 m/z. SIM acqui-
sition was performed using a resolution of 120,000 at 200
m/z, isolation windows of 1.4 m/z with 0.4 m/z offset, target
AGC values of 2 3 105, and a maximum injection time of
230ms. PRM acquisition was performed using a resolution of
60,000 at 200 m/z, isolation windows of 1.4 m/z with 0.4 m/z
offset, target AGC values of 2 3 105, and a maximum injec-
tion time of 130ms. Fragmentation was performed with a
normalized collision energy of 27.
The neutrophil proteomes were analyzed using an LC–MS
instrumentation consisting of an EASY-nLC 1200 system
(Thermo Fisher Scientific) combined with a Q Exactive HF
Orbitrap (Thermo Fisher Scientific) and a nano-electrospray
ion source (Thermo Fisher Scientific). The purified peptides
were separated on a 50cm HPLC column (75 mM inner diam-
eter, in-house packed into the tip with ReproSil-Pur C18-AQ
1.9 mM resin (Dr. Maisch GmbH)). Of each of the 24 fractions
around 0.5mg peptides were analyzed with a 45min gradient.
Peptides were loaded in buffer A (0.1% FA, 5% DMSO (v/v))
and eluted with a linear 35min gradient of 3–30% of buffer B
(0.1% FA, 5% DMSO, 80% (v/v) ACN), followed by a 7min
increase to 75% of buffer B and a 1min increase to 98% of
buffer B, and a 2min wash of 98% buffer B at a flow rate of
450 nl/min. Column temperature was kept at 60 °C by a Pelt-
ier element containing in-house developed oven. MS data
were acquired with a Top15 data-dependent MS/MS scan
method (topN method). Target values for the full scan MS
spectra was 3 3 106 charges in the 300–1650 m/z range with
a maximum injection time of 55ms and a resolution of
120,000 at m/z 200. Fragmentation of precursor ions was
performed by higher-energy C-trap dissociation (HCD) with a
normalized collision energy of 27. MS/MS scans were per-
formed at a resolution of 15,000 at m/z 200 with an ion target
value of 5 3 104 and a maximum injection time of 25ms.
For intact mass analysis, proteins were loaded on a
reversed-phase column (Phenomenex AerisTM 3.6 mM Wide-
pore C4 100mm 3 2.1mm inner diameter, 200Å pore size).
An Agilent 1100 HPLC system was coupled online with the
mass spectrometer (microTOF, Bruker Daltonik) and masses
were recorded from 800–3000 m/z. Proteins were separated
with a binary buffer system of buffer A (0.05% TFA in H2O,
pH 2.0) and buffer B (0.05% TFA in can, pH 2.0) at a flow
rate of 250 nl/min. Proteins were eluted with a gradient of
20–80% buffer B in 20min. After each gradient, the column
was washed with 95% buffer B for 1 min and 20% buffer B
for 3min. Data were processed using the CompassTM ‘Data-
Analysis’ software from Bruker Daltonik, deconvoluted with
‘MaximumEntropy’ and an instrument resolving power of
10,000.
Data Analysis and Development of mxSIM Assay to Calculate
Phosphorylation Stoichiometry—The type of our targeted oc-
cupancy assay is a Tier 2, according to previously published
guidelines (40). For the calculation of absolute Rab10-pThr73
occupancies, raw MS data were processed using Skyline 4.2
(0.19072) (41), which is an open source software project and
can be freely installed. Raw files were directly imported into
Skyline in their native file format. After data import, graphical
displays of chromatographic traces were manually inspected
for proper peak picking of MS1 filtered endogenous peptides
based on co-eluting stable isotope-labeled peptides. All
quantitation performed for phosphorylation occupancy
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calculations in this study were done on the precursor ion
level. Only the most abundant first two peaks of the isotope
cluster were used for quantitation. Peptide areas (AUCs) for
the nonphosphorylated tryptic Rab10 peptide (FHTITTSYYR,
m/z 644.819711) and the phosphorylated tryptic Rab10
peptide (FHpTITTSYYR, m/z 684.802811) with their
r=13C615N4 heavy analogues were extracted to derive
light-to-heavy ratios. The absolute quantification was deter-
mined by comparing the abundance of the known SIL inter-
nal standard peptides with the native peptides. The phospho-
rylation stoichiometry/occupancy is calculated by taking the
ratio of the total amount of phosphorylated fraction to the
total amount of both phosphorylated and nonphosphorylated
forms, which is always represented as percentage (%). When
using mxPRM method, the median ratio of all unique y ions
that belong to the phosphorylated and nonphosphorylated
tryptic Rab10 peptides was used to calculate occupancy. All
details for occupancy calculations in this study are provided
in the supplemental Table S3.
For the deep proteome of human neutrophils, raw MS data
were processed using MaxQuant version 1.5.6.8 (41, 42)
against the Human UniProt FASTA database containing
21,052 entries (UniProt, release 2017) and a list of 245 poten-
tial contaminants. Enzyme specificity was set to trypsin, and
the search included cysteine carbamidomethylation as a
fixed modification and N-acetylation of protein and oxidation
of methionine as variable modifications. Up to two missed
cleavages were allowed for protease digestion, and peptides
had to be fully tryptic. MaxQuant uses individual mass toler-
ances for each peptide, whereas the initial maximum precur-
sor mass tolerances were set to 20ppm in the first search
and 4.5ppm in the main search, and the fragment mass tol-
erance was set to 20ppm. The false discovery rate was con-
trolled with a target-decoy approach at less than 1% for pep-
tide spectrum matches and less than 1% for protein group
identifications.
Bioinformatic analyses in this study were performed with
Perseus (www.perseus-framework.org) (43), Microsoft Excel
and data visualized using GraphPad Prism (GraphPad Soft-
ware) or RStudio (https://www.rstudio.com/).
RESULTS
Rab10-pThr73 Serves as a Readout for LRRK2 Activity in
Human Peripheral Blood Neutrophils—We decided to monitor
Rab phosphorylation in in human peripheral blood neutro-
phils, as these cells can be sampled in a minimally invasive
way. To explore which Rab GTPases were expressed in
these cells and which of them could serve as a readout for
LRRK2 activity in a quantitative MS-based assay, we first iso-
lated neutrophils from whole blood using a negative selection
approach. We assessed the recovery and the purity of the
enriched cells by flow cytometry and found it to be more
than 98%, with. 96% of them viable (supplemental Fig. S1).
Proteomic analysis resulted in 5,488 quantified proteins, for
which we estimated the copy numbers per cell using the pro-
teomic ruler approach (45) (Fig. 1A and supplemental Table
S1). Encouragingly, LRRK2, the vesicular protein VPS35 and
many of the Rab proteins that are LRRK2 substrates were in
the highest quartile of the abundance-ranked proteome (Fig.
1B). The bona-fide LRRK2 substrate Rab10 had the highest
copy number among all detected Rab proteins with an esti-
mated 1,820,000 copies per cell, suggesting its suitability as
a marker for LRRK2 activity in PD (supplemental Fig. S2).
To determine whether Rab10 is the only Rab family mem-
ber that is phosphorylated by LRRK2 in neutrophils, we first
treated freshly isolated cells with the selective LRRK2 in-
hibitor MLi-2 and confirmed the down-regulation of Rab10-
pThr73 by immunoblotting (11) (Fig. 1C). In the same lysates,
we enriched phosphorylated Rab proteins with the previously
described pThr-specific Rab antibody and subjected the
eluates to LC–MS/MS analysis (9). We identified 19 Rab
GTPases in total, of which 7 were previously shown to be
LRRK2 targets (9) (Fig. 1D, supplemental Fig. S3, supplemen-
tal Table S2). In two independent pThr-specific Rab antibody
pulldown experiments, Rab10, Rab43 and Rab8a phospho-
protein levels decreased significantly upon MLi-2 treatment,
indicating that these Rabs are targeted by LRRK2 in this sys-
tem. To directly confirm LRRK2-mediated phosphorylation of
these proteins, we immunoprecipitated them and quantified
Rab10-pThr73, Rab43-pThr82 and Rab8a-pThr72 phospho-
peptides by targeted MS (Selected Ion Monitoring, SIM, see
Experimental procedure). Only Rab10 and Rab43 phospho-
rylation sites were down-regulated more than 4-fold after
LRRK2 inhibitor treatment, demonstrating that the phos-
phorylation status of these Rabs can be used as readout
for LRRK2 kinase activity (Fig. 1E).
The high abundance of Rab10 in neutrophils and the
promise of pThr73 as a biomarker for Parkinson’s disease
encouraged us to develop a highly accurate and sensitive
targeted MS-based assay for quantifying phosphorylated
Rab10 in human cells at the peptide level. To maximize sen-
sitivity, we explored a multiplexed SIM (mxSIM) setup on a
linear quadrupole Orbitrap instrument (Q Exactive HF-X) (46).
In our strategy, the SIL analog of the phosphorylated tryptic
Rab10-Thr73 peptide acts as a sentinel peptide, as it can be
spiked-in in high amounts and elutes simultaneously with its
endogenous light counterpart. Light (endogenous) as well as
SIL counterpart phosphopeptides are consecutively isolated
by narrow quadrupole isolation windows but simultaneously
injected into the Orbitrap mass analyzer. We set the maxi-
mum total ion accumulation time to 230ms, but allocate 90%
of this to the endogenous phosphopeptide, thus boosting its
signal and increasing the sensitivity of our assay many-fold.
To compare the sensitivity and the accuracy of (mx)SIM
with regular full-MS scanning and with PRM, we mixed vari-
able amounts of the SIL Rab10 phosphopeptide (10 amol to
50 fmol) with 50ng of a tryptic Hela digest and measured the
SIL pRab10 peptide intensity using our different scan
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protocols. Relative to full-MS scanning, in which the entire
mass range (300–1650 m/z) is analyzed, SIM, either multi-
plexed or not, provided a 20-fold increase in sensitivity with a
limit of detection (LOD) of 50 amol (Fig. 1F). PRM performed
equally well in terms of sensitivity, however, SIM had a some-
what higher quantification accuracy (R2 of 0.992 versus
0.983). For this reason, and because it was sufficiently spe-
cific in our system, we decided to develop a Rab10-pThr73
quantification assay based on mxSIM.
To determine the maximum heavy-to-light ratio and the
limit of quantification (LOQ) of our method, we mixed 25 fmol
of the light pRab10 peptide with variable amounts of its
heavy counterpart (10 amol to 50 fmol) in 50ng of HeLa
digest. The results for mxSIM indicate excellent reproducibil-
ity of quantification (R2 = 0.997) (Fig. 1G). Because of the dif-
ferential filling strategy, we accurately quantified heavy-to-
light ratios of Rab10 phosphopeptides of up to 1:500 (25 fmol
light and 50 amol heavy Rab10 peptide).
mxSIM Precisely and Accurately Determines Rab10-Thr73
Phosphorylation Stoichiometry—To evaluate protein and pep-
tide-centric approaches for determining Rab10-Thr73 phos-
phorylation stoichiometry, we expressed and purified Rab10
(1-175 aa) from an auxotroph E.coli strain, which allowed for
incorporation of SIL lysine and arginine into the newly synthe-
sized protein (29, 35). We were able to phosphorylate 50% of
the recombinant protein by LRRK2, as shown by intact mass
analysis, and bottom-up proteomics confirmed Thr73 as the
phosphorylation site (supplemental Fig. S4A and S4B). This
is a very suitable proportion as both phosphorylated and
nonphosphorylated peptides are needed as standards and
we therefore decided to use this SIL recombinant phospho-
protein for quantifying the percentage of pRab10 in cells.
For this purpose, we immunoprecipitated HA-Rab10 from
LRRK2-Y1699C-expressing HEK293 cells, either treated with
MLi-2 or not, and mixed the enriched protein with our SIL
standard before joint tryptic digestion (supplemental Fig.
S5A–S5B). We then derived the Rab10-Thr73 phosphoryla-
tion stoichiometry, as described above, to be 66.66 1.5%.
Subsequently, we used the same measurement but calcu-
lated the occupancy with the peptide-centric approach,
yielding 67.26 1.1% occupancy. As both approaches gave
nearly identical results, we decided to use the simpler pep-
tide centric approach for all further calculations (Fig. 2B).
Detection of sub-stoichiometric, post-translationally modi-
fied peptides in complex mixtures by proteomics is challeng-
ing, even with sensitive targeted methods, and requires one
or more upfront enrichment steps. To select a suitable anti-
body for enriching Rab10, we compared one recognizing the
total protein with one recognizing the HA-epitope tag in HA-
Rab10 expressing cells. Unexpectedly, the Rab10 directed
antibody yielded significantly lower apparent pThr73 occu-
pancy as compared with the antibody directed against the
epitope tag (50.960.5% versus 67.261.1%). An likely ex-
planation for this discrepancy could be that the anti-Rab10
antibody preferentially recognizes the nonphosphorylated
fraction of the total protein pool (Fig. 2B and 2C). To address
our challenge with a different approach that does not rely on
antibodies, we separated the cell lysate mixed with the SIL
phosphoprotein standard on SDS-PAGE, excised the region
of ;15-30kDa and digested the proteins using trypsin, fol-
lowed by mxSIM analysis. This resulted in a measured
Rab10-pThr73 occupancy of 70.86 1.0%, in almost perfect
agreement with the occupancy obtained by the anti-HA
immunoprecipitation approach (Fig. 2B and 2C). Finally, we
used SIL phosphorylated and nonphosphorylated peptides
for deriving the Rab10-Thr73 phosphosite occupancy and
again found that 69.761.3% of the protein was phosphoryl-
ated in the same cell lysate; again an almost identical occu-
pancy value as the one obtained from spike-in of the SIL
phosphoprotein (Fig. 2C). We therefore decided to combine
gel-separation, SIL peptide spike-in and the peptide-centric
calculation method. With these tools in hand, we extended
our in-gel digestion workflow to endogenous Rab10-pThr73
occupancy determination. We found that 58.060.9% of the
protein was phosphorylated in LRRK2-Y1699C-transfected
cells, whereas the treatment with MLi-2 almost completely
abolished the phospho-occupancy (0.896 0.03%) (Fig. 2D).
To further benchmark our assay, we incubated recombi-
nant Rab10 (1-175 aa) with LRRK2 and stopped the phos-
phorylation reaction by adding the LRRK2 inhibitor HG-10-
102-0 at defined time intervals. Next, we determined the
percentages of the phosphorylated Rab10 proteins by intact
MS and compared these values to the occupancies obtained
using our mxSIM method (supplemental Fig. S6A–S6D). This
experiment revealed an excellent correlation between these
methods in two independent experiments with R2 of 0.984
and 0.994 (Fig. 2E). To specifically test the SIL peptide spike-
in part of the approach, we mixed SIL phosphorylated and
nonphosphorylated Rab10 peptides in 1:9, 1:2.3, 1:1, 2.3:1,
and 9:1 ratios to mimic phosphosite occupancies of 10, 30,
50, 70, and 90%, respectively, and mixed them with our
recombinant Rab10 phosphoprotein. We then derived the
Rab10-pThr73 occupancy based on the heavy-to-light ratios
of both phosphorylated and nonphosphorylated peptides
(Fig. 2F). The calculated mean occupancy for our recombi-
nant Rab10 phosphoprotein was 75.36 1.5%, for mxSIM
and 70% for intact mass analysis. We also measured the
Rab10-pThr73 occupancy of the same recombinant protein
and obtained 77.460.4% for PRM and 77.660.6% for
mxSIM (supplemental Fig. S7A). Finally, we determined the
analytical, the intra- and the inter-assay variabilities, which
yielded excellent coefficients of variations (CVs) of 1.9%,
8.7% and 13.0%, respectively (Fig. 2G). This demonstrates
that our mxSIM assay is highly accurate and reproducible.
In-Gel Digestion Combined with mxSIM Can Detect Subtle
Changes in Rab10-Thr73 Phosphorylation within Cells—Most
pathogenic LRRK2 mutations, including R1441C/G/H, increase
LRRK2 kinase activity and significantly stimulate Rab10 protein
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phosphorylation in mouse and human cells and tissues (6–9).
To determine whether our assay was sufficiently accurate and
robust to detect small differences of LRRK2 activity in cells, we
treated WT and LRRK2 R1441G knock-in mouse embryonic
fibroblasts (MEFs) with increasing concentrations of MLi-2 and
determined Rab10-Thr73 phosphorylation occupancies (Fig.
3A). In parallel, we controlled LRRK2 inhibitor efficacy by im-
munoblotting and probing for Rab10-pThr73 (Fig. 3B). Com-
pared with WT, in which the Rab10-pThr73 occupancy was
12.16 0.6%, we found a 2.45-fold increase in R1441G
(29.76 0.9%) (Fig. 3C). Rab10-pThr73 occupancy already
decreased by 1.5-fold (18.86 1.5%) upon treatment with
1nM of MLi-2 and by almost 2-fold (15.46 0.7%) with 3nM of
the inhibitor (Fig. 3B–3C). The corresponding Rab10-pThr73
immunoblot signals also showed some decrease, however,
reliable and precise quantification of these bands was difficult.
FIG. 2.mxSIM accurately determines Rab10-Thr73 phosphorylation stoichiometry. A, Heavy-to-light ratios and the formulas used for pro-
tein- and peptide-centric approaches. B, HA-Rab10-pThr73 occupancy in LRRK2-Y1699C-expressing HEK293 cells was determined using the
protein- versus peptide-centric approaches after HA-IP.C, HA-Rab10-pThr73 occupancy determined using the peptide-centric approach with ei-
ther SIL phosphoprotein or SIL peptide standard spike-in after enrichment by anti-Rab10-IP or SDS-PAGE followed by in-gel digestion in HEK293
cells expressing LRRK2-Y1699C (2/1 200nMMLi-2, 60min).D, Endogenous Rab10-pThr73 occupancy determined using SIL peptide standards
in mock and LRRK2-Y1699C expressing HEK293 cells (2/1 200nM MLi-2, 60min). Samples from (B), (C), and (D) were analyzed in triplicates
using themxSIMmethod and the phosphorylation occupancies are presented asmeans6 SEM. E, Benchmarking our method using Thr73-phos-
phorylated unlabeled recombinant Rab10 proteins (1-175 aa) as standards. Correlation of the median occupancies determined either by intact
mass analysis or by mxSIM in triplicates for two independent experiments. F, SIL phosphorylated and nonphosphorylated Rab10 peptides mixed
tomimic 10, 30, 50, 70, and 90%occupancies and spiked into the digested recombinant pRab10 protein weremeasured using ourmxSIMmethod
in triplicates. The solid line represents the median occupancy (75.461.5%) whereas the dashed line shows the estimated phosphorylation occu-
pancy of the standard protein (70%) by intact mass analysis. G, CVs were calculated by repeating MSmeasurements (analytical), the workflow in
the same gel (intra-assay) or in different gels (inter-assay) using the same phosphoprotein standard (n=6).
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We reasoned that our data should also allow determination
Rab10-pThr73 IC50 of MLi-2 directly from the occupancies. We
extracted a value of 3nM, well within the 3-10nM range esti-
mated by our previous phos-tag Rab10 analysis (Fig. 3D) (12).
Together, our results establish that our assay can reliably detect
small differences in phosphorylation occupancy in cultured cells.
We next addressed our main objective: to determine
whether our assay is suitable and sufficiently sensitive for
quantifying the percentage of Rab10-pThr73 in human pe-
ripheral blood. To this end, we isolated neutrophils from five
healthy volunteers. Upon treatment with either 30nM or
100nM of MLi-2, we found a decrease in Rab10-pThr73 by
immunoblotting (Fig. 3E). Judged by this, the level of phos-
phorylated Rab10 protein was low in all individuals. Applying
our workflow in the manner described above, showed that
the median occupancy was 2.36 0.2% in DMSO-treated
cells and that it decreased to 1.36 0.1% after 30nM and
to 0.66 0.1% after 100nM MLi-2 treatment (Fig. 3F). These
occupancies correspond to 225,500615,500 (DMSO),
115,27066190 (30nM MLi-2) and 60,1606 4600 (100nM
FIG. 3.Reliable determination of Rab10-pThr73 occupancy in cell lysates.A, Workflow for the Rab10-pThr73 occupancy assay.B, Immuno-
blotting of WT and R1441G knock-in MEFs treated with the indicated concentrations of MLi-2 for different intervals using monoclonal MJFF-
pRAB10 (pThr73) and GAPDH antibodies. C, Rab10-pThr73 occupancies were determined by mxSIM in the same lysates (n=3). D, Dose–
response curve of Rab10-pThr73 occupancy in R1441G knock-in MEFs to generate occupancy based-IC50 values for MLi-2. Each data point
represents the median of triplicate measurements in the samples treated with MLi-2 for 90min. E, Immunoblotting of neutrophils isolated from
healthy individuals (DMSO or 30 and 100nM MLi-2 treated) using monoclonal MJFF-pRAB10 (pThr73) and GAPDH antibodies. F, Rab10-pThr73
occupancies were determined by mxSIM in the same lysates. Normalized Rab10- pThr73 occupancies by subtracting the MLi-2 treated values
are shown in red. G, Immunoblotting of the neutrophils isolated from healthy individuals and treated with the indicated concentrations of MLi-2
using monoclonal MJFF-pRAB10 (pThr73) and GAPDH antibodies. H, Individual-specific dose–response curves to generate occupancy based-
IC50 forMLi-2. Error bars represent SEM.
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MLi-2) phosphorylated Rab10 molecules per cells (supple-
mental Table S3) We independently confirmed these results
by PRM (supplemental Fig. S7B).
Intriguingly, the residual Rab10-pThr73 signal after MLi-2
treatment suggested that a kinase other than LRRK2 acts on
this site. This finding raises interesting questions about the
disease mechanism but in our current context, it presents a
source of variability. To account for this, we corrected the
occupancies of each untreated sample by subtracting the
corresponding baseline occupancy (after MLi-2-treatment).
This better separated disease phenotypes in clinical cohorts
(Fig. 3F). Finally, we measured a MLi-2 dose-response curve
(1–100nM) using neutrophils from two donors and determined
their occupancy based-IC50 values. These were similar in
both donors (2.4 nM and 3nM), further demonstrating the high
reproducibility of our method even in vivo (Fig. 3G and H).
PD Patients Have Increased Rab10-Thr73 Phosphorylation
Stoichiometry—The frequency of the LRRK2 G2019S muta-
tion is 1% in patients with sporadic PD and 4% in hereditary
PD patients with up to 30–40% in certain populations such
as Ashkenazi Jews and North African Berbers (4). To investi-
gate the central question of whether our assay can stratify
PD patients with elevated LRRK2 activity in clinical trials, we
analyzed Rab10-pThr73 levels in neutrophils of four LRRK2-
G2019S carriers with PD, together with an equal number of
healthy controls in a blinded experimental setup (see Experi-
mental Procedures, supplemental Table S4). Each neutrophil
population was treated with DMSO or 100nM MLi-2 and all
samples were subjected to quantitative immunoblot analysis
for Rab10-pThr73 levels, revealing a clear reduction in Rab10
phosphorylation upon LRRK2 inhibition (Fig. 4A). LRRK2-
pSer935 levels were also monitored by immunoblot analysis
in the lysates to confirm the efficacy of MLi-2 treatment. Total
Rab10 levels did not differ between the various genotypes
(Fig. 4A). We quantified Rab10 phosphorylation by normaliz-
ing it with either total Rab10 or GAPDH (Fig. 4B). Although
the data show that Rab10-pThr73 levels are slightly in-
creased in G2019S carriers when normalized with GAPDH,
the observed differences did not reach statistical signifi-
cance (Fig. 4B). The median occupancy of normalized Rab10-
pThr73 was 1.86 0.3% in healthy controls and increased by
almost 2-fold (3.366 0.4%) in G2019S carriers (Fig. 4C–4D).
In MLi-2 treated samples, the occupancy decreased 5-fold on
average for both groups. Despite a good correlation between
the two measurements (r=0.59), MS-based quantification
was better at separating controls from G2019S carriers (p =
0.019) (Fig. 4E).
Our previous work demonstrated that VPS35 controled
LRRK2 activity and that the D620N substitution resulted in
increased LRRK2 activity as assessed by monitoring phos-
pho-Rabs levels (15). To test if our assay can determine
LRRK2 activity in PD patients with the VPS35 D620N muta-
tion, we measured Rab10-Thr73 phosphorylation occupan-
cies in neutrophils isolated from three heterozygous patients,
as well as three age-matched idiopathic PD patients and
three nonPD controls (see Experimental Procedure, supple-
mental Table S4). We treated the neutrophils from each sub-
ject with either DMSO or 200nM MLi-2 before cell lysis. In ac-
cordance with our previous work, immunoblot analysis
revealed significantly elevated Rab10-pThr73 levels in VPS35
D620N patients (Fig. 4F–4G). The median occupancies were
0.66 0.1%, 0.86 0.1% and 1.96 0.5% in healthy controls,
idiopathic and heterozygous VPS35 D620N patients, respec-
tively, and decreased 6.9-fold on average in MLi-2 treated
cells (Fig. 4H). Our MS-based assay also confirmed signifi-
cantly higher levels of Rab10-pThr73 levels in VPS35 D620N
patients compared with controls and idiopathic cases and
we observed a very good correlation between the two meas-
urements (r=0.79) (Fig. 4I–4J). Compared with controls, there
was 1.5-fold increase in Rab10-pThr73 levels in idiopathic
PD with both assays, however, the coefficient of variation in
the control group was 30% with the mxSIM occupancy assay
and 51% by immunoblotting (Fig. 4G- and 4I).
In conclusion, we here determined pRab10 occupancies in
neutrophils of 7 healthy controls and 7 PD patients with
defined mutations (four LRRK2 G2019S and three VPS35
D620N). Compared with healthy controls, neutrophils of
mutation carriers with PD robustly displayed a higher fraction
of phosphorylated Rab10, namely a 2.2-fold increase in
pRab10 levels (p-value ,0.05) (Fig. 4K). These results dem-
onstrate that our assay can accurately ascertain the LRRK2
kinase activity in human derived samples, including its in-
crease in mutation carriers, and suggest that it can be
applied to stratify patients.
DISCUSSION
Here, we have established an accurate and highly-sensitive
MS-based assay for determining the percentage of Rab10-
Thr73 phosphorylation in samples collected from PD patients.
Using stable-isotope labeled spike-in peptides and a differen-
tial filling strategy for an Orbitrap analyzer, our range of quan-
tification extended down to 50 attomoles and we were able
to capture phosphorylation differences as small as those
characterize controls and mutation carriers (1.26% to 2.73 in
our human neutrophil samples). We confirmed Rab10-Thr73
phosphorylation as a direct readout for LRRK2 activity and
specifically applied our assay to monitor LRRK2 activity in
human neutrophils. We found that these cells contain rela-
tively high levels of both LRRK2 and Rab10 and that their iso-
lation is straightforward, although rapid isolation with minimal
protease activation is important (11). As a next step, it will be
interesting to investigate whether pRab10 can be detected in
postmortem brain tissues or bodily fluids such as cerebrospinal
fluid (CSF) and urine. Large and readily accessible collections
of these bio-fluids could be used to further establish pRab10
as a bona-fide biomarker for PD disease progression.
After careful evaluation of spike-in standard type (SIL
phosphoprotein versus peptides) and occupancy
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FIG. 4.Rab10-pThr73 occupancy in PD patient-derived neutrophils.A, Immunoblotting of neutrophils isolated from four PD patients with the
G2019S LRRK2 mutation and four healthy controls (2/1100nM MLi-2, 30min) using anti total LRRK2, pSer935 LRRK2, total Rab10, MJFF-
pRAB10 (pThr73) and GAPDH antibodies. B, Quantitation of immunoblots by analyzing phospho-Thr73 Rab10/total Rab10 ratio (right) and phos-
pho-Thr73 Rab10/GAPDH ratio (left panel). C, Blind application of our mxSIM assay to the same mock (black) and MLi2-treated (grey) lysates
(n=3). NormalizedRab10- pThr73 occupancies by subtracting theMLi-2 treated values are also shown (red). Error bars represent SEM.D, Quanti-
fication of Rab10-pThr73 occupancy in controls and PD patients with theG2019S LRRK2mutation. Each data point represents themedian of trip-
licate measurements of untreated samples that are normalized toMLi2. One-way ANOVAwith Bonferroni's multiple comparisons test was applied
and the occupancies are presented asmeans6 SEM. E, Pearson correlation between immunoblotting andmxSIM assay. Plotted are fold changes
of normalized Rab10-pThr73 levels (occupancies inmxSIM) relative to control cases. F, Immunoblotting of neutrophils isolated from controls, idio-
pathic PD patients and heterogeneous VPS35 D620N mutation carriers (2/1 200nM MLi-2, 30min) using anti-total LRRK2, pSer935 LRRK2, total
Rab10, MJFF-pRAB10 (pThr73) and GAPDH antibodies. G, Quantitation of immunoblots by analyzing phospho-Thr73 Rab10/total Rab10 ratio
(right) and phospho-Thr73 Rab10/GAPDH ratio (left panel). H, Blind application of our assay to the same mock (black) and MLi2-treated (grey)
lysates (n=3). Normalized Rab10- pThr73 occupancies by subtracting the MLi-2 treated values are shown in red. Error bars represent SEM. I,
Quantification of Rab10-pThr73 occupancy in controls, idiopathic PD and PD patients with heterogeneous VPS35 D620Nmutation. The significant
analysis was done as in (D). J, Same as (E) with healty controls (HC), idiopathic PD (iPD) and VPS35 D620N (VPS35). K, Quantification of Rab10-
pThr73 occupancy between controls, idiopathic cases and PDpatients with a definedmutation. The significant analysis was done as in (D).
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calculation approach (protein- versus peptide-centric
approach), we opted for the peptide-centric approach in
conjunction with the use of SIL peptides standards.
Although spike-in of a labeled protein has the advantage
of automatically accounting for the digestion efficiency,
addition of labeled peptides makes the occupancy deter-
mination more generally applicable, as labeled peptides
can readily be obtained at very high purity.
Furthermore, our assay uses separation of Rab10 by
SDS-PAGE, which is followed by in-gel digestion. This
strategy substantially enriches Rab10 and allows quanti-
fying Rab phosphorylation with high sensitivity. When
applied to large cohorts, a limitation of our assay is its low
throughput. To solve this, the in-gel step in our workflow
should be eliminated and as alternative antibodies that
recognize both GDP and GTP bound Rab10 could be
employed. There are considerable efforts currently being
invested into producing these tools 14. Alternatively, non-
hydrolyzable GTP analogues could be used to enrich Rab
proteins before MS analysis.
We determined pRab10 occupancy in neutrophils of 14
healthy controls, three idiopathic PD patients, four LRRK2
G2019S and three VPS35 D620N mutation carriers with PD.
Despite the small number of patients and the large intragroup
variability, the difference between control and PD cases with
LRRK2 G2019S and VPS35 D620N mutations reached statis-
tical significance. Analysis of larger cohorts and inclusion of
patient samples with higher LRRK2 activity, such as the
R1441G/C mutations, should add statistical power and fur-
ther establish pRab10 occupancy as a bona-fide marker of
LRRK2 activity in PD. It will be exciting to investigate whether
PD patients with increased pRab10 levels would also benefit
from LRRK2 inhibitor treatment.
We find that the levels of Rab10-Thr73 phosphorylation
are stable but very low in human neutrophils. This is also true
for PD-associated LRRK2-G2019S mutation carriers where
activation of the LRRK2 kinase is modest whereas individuals
with a VPS35 D620N mutation demonstrate much higher
Rab10-Thr73 phosphorylation, reflecting its much greater
catalytic effect on the LRRK2 kinase. Our results show that
changes in pRab10 can be used as direct readout for LRRK2
activity and the very low percentage of pRab10 that we
observe ex vivo may explain the age-dependent, incomplete
penetrance of the LRRK2 G2019S mutation. It will be inter-
esting to compare pRab10 percentages of matched disease-
manifesting and nonmanifesting LRRK2 G2019S mutation
carriers at younger and older ages.
Our results could explain how minimal changes in the
total pool of a phosphorylated protein could trigger patho-
genesis. Stratification for Rab10-pThr73 levels in idio-
pathic and mutation carrying PD patients may identify
individuals with increased LRRK2 kinase activity who
would most likely benefit from LRRK2 kinase inhibitor
treatment. Furthermore, our mass spectrometric assay is
completely generic and not restricted to a disease. It
could be applied to study any other kinase-substrate rela-
tion in clinical research. For example, phosphosite occu-
pancies of prominent oncogenic factors could give impor-
tant information on how phosphorylation stoichiometry
influences tumorigenesis (14).
In summary, our generic and sensitive MS-based assay
accurately measures phosphorylation stoichiometry of sub-
strates of interest. Presently, it can be used for ongoing clini-
cal LRRK2 inhibitor studies, in which the target engagement,
dosing and efficacy of the compounds needs to be eval-
uated, and we are currently pursuing this. We envision that
our assay can also be applied to further investigate the role
of LRRK2 in the PD, potentially revealing new upstream play-
ers of LRRK2 pathway, and determining whether they have a
potential in treating PD.
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